Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Helius Medical Technologies ( (HSDT) ) is now available.
On June 20, 2025, Helius Medical Technologies‘ Board of Directors approved a 1-for-50 reverse stock split of its Class A common stock, effective July 1, 2025, to meet Nasdaq’s listing requirements. This move will reduce the number of outstanding shares from approximately 33.8 million to 0.7 million, while the stock will continue trading under the symbol ‘HSDT’ on a split-adjusted basis starting July 1, 2025.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies’ stock score is primarily impacted by its poor financial performance and bearish technical indicators. Valuation challenges further weigh down the score. The recent capital raise provides temporary relief, but significant operational improvements are needed for a positive outlook.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Helius Medical Technologies, Inc. operates in the medical technology industry, focusing on developing non-invasive platform technologies that amplify the brain’s ability to heal itself. The company’s primary product is the Portable Neuromodulation Stimulator (PoNS), which is designed to treat neurological symptoms caused by disease or trauma.
Average Trading Volume: 6,060,054
Technical Sentiment Signal: Strong Sell
Current Market Cap: $171.6K
Find detailed analytics on HSDT stock on TipRanks’ Stock Analysis page.